Expression of Interleukin-22 in Myasthenia Gravis

Scandinavian Journal of Immunology

Volumn 78, Issue 1, 2013, Pages 98-107

  Zheng, S ^a   Dou, C ^a   Xin, N ^a   Wang, J ^a,a   Li, P ^a   Fu, L ^a   Shen, X ^a   Cui, G ^a   Dong, R ^a   Lu, J ^a   Zhang, Y ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 22;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; MALE; MYASTHENIA GRAVIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AUTOANTIBODIES; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKINS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC;

EID: 84880260826     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12057     Document Type: Article

References (41)

1. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357:2122-8.
2. Huang S, Tan LM. Research advancement in immunopathogenesis of myasthenia gravis. Neurosci Bull 2010;26:85-9.
3. Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 1978;28:266-72.
4. Farrugia ME, Jacob S, Sarrigiannis PG, Kennet RP. Correlating extent of neuromuscular instability with acetylcholine receptor antibodies. Muscle Nerve 2009;39:489-93.
5. Hughes BW, Moro De Casillas ML, Kaminski HJ. Pathophysiology of myasthenia gravis. Semin Neurol 2004;24:21-30.
6. Elson CJ, Barker RN. Helper T cells in antibody-mediated, organ-specific autoimmunity. Curr Opin Immunol 2000;12:664-9.
7. Bai Y, Liu R, Huang D et al. CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur J Immunol 2008;38:1877-88.
8. Roche JC, Capablo JL, Larrad L et al. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 2011;44:278-80.
9. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol 2010;32 17-31.
10. Pan HF, Zhao XF, Yuan H et al. Decreased serum IL- 22 levels in patients with systemic lupus erythematosus. Clin Chim Acta 2009;401:179-80.
11. Cheng F, Guo Z, Xu H, Yan D, Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009;68:604-6.
12. Ziesche E, Scheiermann P, Bachmann M et al. Dexamethasone suppresses interleukin-22 associated with bacterial infection in vitro and in vivo. Clin Exp Immunol 2009;157:370-6.
13. Qin WZ, Chen LL, Pan HF et al. Expressions of IL-22 in circulating CD4+/CD8+ T cells and their correlation with disease activity in SLE patients. Clin Exp Med 2011;11:245-50.
14. Yu B, Guan M, Peng Y et al. Copy number variations of interleukin-17F, interleukin-21, and interleukin-22 are associated with systemic lupus erythematosus. Arthritis Rheum 2011;63:3487-92.
15. Ikeuchi H, Kuroiwa T, Hiramatsu N et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005;52:1037-46.
16. Geboes L, Dumoutier L, Kelchtermans H et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009;60:390-5.
17. da Rocha LF Jr, Duarte AL, Dantas AT et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol 2012;39:1320-5.
18. Leipe J, Schramm MA, Grunke M et al. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2011;70:1453-7.
19. Kim KW, Kim HR, Park JY et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum 2012;64:1015-23.
20. Vandenbroeck K, Alvarez J, Swaminathan B et al. A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. Genes Immun 2012;13:21-8.
21. Beyeen AD, Adzemovic MZ, Ockinger J et al. IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. J Immunol 2010;185:6883-90.
22. Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, et al. IL- 22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007;179:8098-104.
23. Lavoie TN, Stewart CM, Berg KM, Li Y, Nguyen CQ. Expression of interleukin-22 in Sjogren's syndrome: significant correlation with disease parameters. Scand J Immunol 2011;74:377-82.
24. Ciccia F, Guggino G, Rizzo A et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2012;71:295-301.
25. Wolk K, Haugen HS, Xu W et al. IL-22 and IL- 20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) 2009;87:523-36.
26. Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51.
27. Drachman DB. Medical progress: myasthenia gravis. N Engl J Med 1994;330:1797-810.
28. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971;38:497-537.
29. Yang H, Goluszko E, David C et al. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J Clin Invest 2002;109:1111-20.
30. Yoshikawa H, Satoh K, Yasukawa Y, Yamada M. Cytokine secretion by peripheral blood mononuclear cells in myasthenia gravis. J Clin Neurosci 2002;9:133-6.
31. Moschen AR, Geiger S, Krehan I, Kaser A, Tilg H. Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology 2008;213:779-87.
32. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007;27:647-59.
33. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008;29:947-57.
34. Sugimoto K, Ogawa A, Mizoguchi E et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008;118:534-44.
35. Chang H, Hanawa H, Liu H et al. Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats. J Immunol 2006;177:3635-43.
36. Besnard AG, Sabat R, Dumoutier L et al. Dual Role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am J Respir Crit Care Med 2011;183:1153-63.
37. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004;39:1332-42.
38. Smith E, Stark MA, Zarbock A et al. IL-17A inhibits the expansion of IL-17A-producing T cells in mice through "short-loop" inhibition via IL-17 receptor. J Immunol 2008;181:1357-64.
39. von Vietinghoff S, Ley K. IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J Immunol 2009;183:865-73.
40. Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser LA, Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010;207:1293-305.
41. Ke Y, Sun D, Jiang G, Kaplan HJ, Shao H. IL-22-induced regulatory CD11b+ APCs suppress experimental autoimmune uveitis. J Immunol 2011;187:2130-9.